Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01050790 · OUTCOME

Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma · Source last updated 2018-06-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
6 months

What was measured

Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment.

Analysis population: 17 of 17 patients were able to mobilize lymphocytes. 16 of 17 patients had lymphocytes infused post transplant. 1 patient was not able to mobilize stem cells and so did not go to transplant.

Groups in this outcome

5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant

azacitidine: 75 mg/sq m daily for 5 days lenalidomide: 10 mg p.o. daily, Days 6-21

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant17

Reported measurements

mobilize lymphocytes
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant17Not reportedNot reportedNot reportedNot reported
lymphocytes infused post transplant
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant16Not reportedNot reportedNot reportedNot reported
not able to mobilize stem cells/no transplant
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    title
    mobilize lymphocytes
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        16
    title
    lymphocytes infused post transplant
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        1
    title
    not able to mobilize stem cells/no transplant
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment.
groups
  1. description
    azacitidine: 75 mg/sq m daily for 5 days lenalidomide: 10 mg p.o. daily, Days 6-21
    id
    OG000
    title
    5-azacytidine + Lenalidomide -> Auto Stem Cell Transplant
param Type
NUMBER
population Description
17 of 17 patients were able to mobilize lymphocytes. 16 of 17 patients had lymphocytes infused post transplant. 1 patient was not able to mobilize stem cells and so did not go to transplant.
reporting Status
POSTED
time Frame
6 months
title
Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice